REGNRegeneron PharmaceuticalsRunning, no new patients
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
15Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jul 2025, none posted yet
Counts until it's fixed
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score15
Score over time
- Stage
- Phase 3
- Patients
- 288 (final count)
- Started
- Dec 14, 2021
- Main results expected
- Jul 8, 2025
- Fully finished
- Nov 11, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score
Measured over: From baseline to week 24
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-07-08, no fading
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05070858 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC